ACCENT Trial Achieves Superiority over Chemotherapy Alone
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Completion of Recruitment of ACCENT Trial
- Security Class Reinstatement to Quotation - ATXOA
- App 4D and Financial Report Half Year ended 30 Sep 2024
- Security Class Suspension from Quotation
- Amplia Successfully Completes Institutional Offer
Later from Amplia Therapeutics
- Preliminary Final Report and Annual Report YE 31 March 2025
- Pathological Complete Response in Pancreatic Cancer Trial
- Pathological complete response recorded in patient from ACCENT cancer trial
- Second Complete Response in ACCENT Pancreatic Cancer Trial
- Amplia announces A$25m Placement and Launches A$2.5m SPP
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics